SPONTAN® Shows Positive Real-World Outcomes in Younger Men with Performance-Related Erectile Difficulties

A small, independent observational case series in men experiencing situational erectile difficulties associated with sexual performance anxiety has reported positive outcomes with SPONTAN®, LTR Pharma’s intranasal erectile dysfunction product. 

The real-world observations involved five physically healthy men aged 20–30 years who self-identified as experiencing intermittent difficulty maintaining erections during partnered sexual activity, which they attributed to sexual performance anxiety.  

SPONTAN nasal spray was used 10–20 minutes prior to partnered sexual activity. All five participants reported achieving and maintaining an erection sufficient for intercourse when using SPONTAN. 

Sexual performance anxiety is one of the most common male sexual complaints, with published literature suggesting it affects approximately 9–25% of men, particularly younger men without underlying organic erectile dysfunction. 

Melissa Hadley Barrett, Nurse Practitioner and Sexologist, said: 

“Sexual performance anxiety is a common issue in younger men who are otherwise physically healthy. In my clinical experience, the rapid onset associated with SPONTAN may be particularly relevant for men with situational erectile difficulties, where timing and confidence play a significant role. While these observations are preliminary, they highlight an area where further structured clinical investigation is warranted.” 

Based on these preliminary observational findings, LTR Pharma intends to evaluate the potential for a clinician-initiated clinical study in this underserved population in the coming year. 

Click to read the ASX release.